<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">Colorectal cancer</z:e> is the third most prevalent <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> and a leading cause of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">Metastatic colorectal cancer</z:e> patients are treated with anti-EGFR monoclonal antibodies in combination with chemotherapy; however, the efficiency is only 10-20% of such patients </plain></SENT>
<SENT sid="2" pm="."><plain>An increasing amount of data has demonstrated that response to anti-EGFR therapies is confined to patients with KRAS and BRAF <z:mp ids='MP_0002169'>wild type</z:mp> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> but still some of these patients are non responders to this treatment </plain></SENT>
<SENT sid="3" pm="."><plain>The presence of oncogenic deregulation of different members of EGFR downstream signaling or crosstalk molecules could predict the lack of response in these patients </plain></SENT>
<SENT sid="4" pm="."><plain>In this study, 40 <z:mp ids='MP_0002169'>wild type</z:mp> KRAS and BRAF <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumors</z:e> were analyzed to elucidate whether PML-RARa bcr1 fusion gene may play a role in colorectal <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Specifically we want to determine if this fusion could be responsible for the inability to respond to anti-EGFR monoclonal antibodies </plain></SENT>
<SENT sid="6" pm="."><plain>Here, for the first time it is reported, that PML-RARa bcr1 fusion is not responsible for <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumor</z:e> development and also, this translocation is not predicting the lack of efficacy of anti-EGFR therapies in <z:mp ids='MP_0002169'>wild type</z:mp> KRAS and BRAF <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients </plain></SENT>
<SENT sid="7" pm="."><plain>These results also suggest that PML-RARa is unlikely to be a promising target for adjuvant therapy in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients </plain></SENT>
</text></document>